Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
11
12
2020
accepted:
16
03
2021
pubmed:
17
7
2021
medline:
12
11
2021
entrez:
16
7
2021
Statut:
epublish
Résumé
The phase 3 LIBERTY ASTHMA QUEST study (ClinicalTrials.gov: NCT02414854) in patients with uncontrolled, moderate-to-severe asthma has demonstrated the efficacy and safety of dupilumab 200 and 300 mg every 2 weeks Annualised severe exacerbation rates over the 52-week treatment period, pre-bronchodilator forced expiratory volume in 1 s (FEV Across all type 2-high subgroups, dupilumab Dupilumab significantly reduced severe exacerbations and improved FEV
Sections du résumé
BACKGROUND
The phase 3 LIBERTY ASTHMA QUEST study (ClinicalTrials.gov: NCT02414854) in patients with uncontrolled, moderate-to-severe asthma has demonstrated the efficacy and safety of dupilumab 200 and 300 mg every 2 weeks
METHODS
Annualised severe exacerbation rates over the 52-week treatment period, pre-bronchodilator forced expiratory volume in 1 s (FEV
RESULTS
Across all type 2-high subgroups, dupilumab
CONCLUSIONS
Dupilumab significantly reduced severe exacerbations and improved FEV
Identifiants
pubmed: 34266940
pii: 13993003.04498-2020
doi: 10.1183/13993003.04498-2020
pmc: PMC8551561
pii:
doi:
Substances chimiques
Anti-Asthmatic Agents
0
Antibodies, Monoclonal, Humanized
0
dupilumab
420K487FSG
Banques de données
ClinicalTrials.gov
['NCT02414854']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright ©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: J. Corren reports nonfinancial support for research from Sanofi, outside the submitted work. Conflict of interest: C.H. Katelaris reports nonfinancial support (advisory board member and principal study investigator) from Sanofi, outside the submitted work. Conflict of interest: M. Castro reports nonfinancial support for research from the American Lung Association, Gossamer, NIH, PCORI and Shionogi, personal fees for lectures and nonfinancial support for research from AstraZeneca, personal fees for lectures and consultancy, and nonfinancial support for research from Boehringer Ingelheim and Sanofi, personal fees for consultancy and nonfinancial support for research from Novartis, personal fees for consultancy from Boston Scientific and Vida Pharma, personal fees for lectures and consultancy from Teva, personal fees for lectures from Genentech and Regeneron Pharmaceuticals, Inc., personal fees (royalties) from Elsevier, outside the submitted work. Conflict of interest: J.F. Maspero reports being a speaker for AstraZeneca, GlaxoSmithKline, Menarini, Novartis, Sanofi, Teva and Uriach; and has received research grants from Novartis, outside the submitted work. Conflict of interest: L.B. Ford reports nonfinancial support for research from AstraZeneca, DBV, Genentech, Gossamer, Novartis and Teva, personal fees for consultancy from Sanofi, outside the submitted work. Conflict of interest: D.M.G. Halpin reports personal fees for lectures and advisory board work from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Novartis, Pfizer, Sandoz and Sanofi, outside the submitted work. Conflict of interest: M.S. Rice is an employee of Sanofi and may hold stock and/or stock options in the company. Conflict of interest: A. Radwan is an employee and shareholder of Regeneron Pharmaceuticals, Inc. Conflict of interest: Y. Deniz is an employee and shareholder of Regeneron Pharmaceuticals, Inc. Conflict of interest: P.J. Rowe is an employee of Sanofi and may hold stock and/or stock options in the company. Conflict of interest: A. Teper is a former employee of Sanofi. Conflict of interest: M. Djandji is an employee of Sanofi and may hold stock and/or stock options in the company.
Références
Cell. 2010 Mar 19;140(6):777-83
pubmed: 20303868
Adv Ther. 2018 May;35(5):737-748
pubmed: 29725983
Lancet. 2016 Jan 2;387(10013):40-52
pubmed: 26454361
Respir Med. 2006 Mar;100(3):434-50
pubmed: 16099149
Lancet. 2019 Nov 2;394(10209):1638-1650
pubmed: 31543428
Expert Rev Clin Immunol. 2017 May;13(5):425-437
pubmed: 28277826
Nat Rev Immunol. 2015 Jan;15(1):57-65
pubmed: 25534623
Lancet. 2017 Jun 10;389(10086):2287-2303
pubmed: 28478972
Thorax. 2006 Sep;61(9):809-16
pubmed: 16936237
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
Allergy. 2020 May;75(5):1188-1204
pubmed: 31838750
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5153-8
pubmed: 24706856
Respir Med. 2005 May;99(5):553-8
pubmed: 15823451
Eur Respir J. 2019 Jul 18;54(1):
pubmed: 31048346
Allergol Int. 2017 Oct;66(4):568-573
pubmed: 28318883
N Engl J Med. 2016 Dec 15;375(24):2335-2348
pubmed: 27690741
Respir Med. 2007 Mar;101(3):481-9
pubmed: 16914299
N Engl J Med. 2018 Jun 28;378(26):2475-2485
pubmed: 29782224
Respir Res. 2019 Aug 8;20(1):179
pubmed: 31395084
Am J Respir Crit Care Med. 2006 Sep 15;174(6):633-8
pubmed: 16778163
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5147-52
pubmed: 24706858
Lancet. 2016 Jul 2;388(10039):31-44
pubmed: 27130691